Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587102 | 1.00 | CYP2B6 (0.37) | CYP2B6NPC1HRH3ALDH1A1KMT2A | |
| SCHEMBL178517 | 0.97 | CYP2B6 (0.33) | CYP2B6NPC1HRH3TSHRTDP1 | |
| SCHEMBL18059326 | 0.92 | — | — | |
| SCHEMBL21121000 | 0.85 | HRH3 (0.38) | HRH3ALDH1A1TSHRTDP1 | |
| SCHEMBL24419835 | 0.82 | HRH3 (0.33) | HRH3 | |
| SCHEMBL21207913 | 0.80 | CYP2B6 (0.32) | CYP2B6NPC1 | |
| SCHEMBL22871678 | 0.80 | CYP2B6 (0.38) | CYP2B6NPC1KMT2A | |
| SCHEMBL23336586 | 0.80 | CYP2B6 (0.38) | CYP2B6NPC1KMT2A | |
| SCHEMBL11990045 | 0.79 | CYP2B6 (0.34) | CYP2B6NPC1 | |
| SCHEMBL18745418 | 0.79 | CYP2B6 (0.34) | CYP2B6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612313-B2 | Method for producing lithium halide compound | IDEMITSU KOSAN CO., LTD. (JP) | 2026-04-28 | — | — | US | disclosed |
| US-20260008676-A1 | METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE | IDEMITSU KOSAN CO.,LTD. (JP) | 2026-01-08 | — | — | US | disclosed |
| US-20250372697-A1 | METHOD FOR PRODUCING SOLID ELECTROLYTE, AND ELECTROLYTE PRECURSOR | IDEMITSU KOSAN CO.,LTD. (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4657469-A1 | METHOD FOR PRODUCING SULFIDE SOLID ELECTROLYTE | Idemitsu Kosan Co.,Ltd. (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4159678-B1 | METHOD FOR PRODUCING LITHIUM HALIDE COMPOUND | IDEMITSU KOSAN CO (JP) | 2025-10-01 | — | — | EP | disclosed |
| US-12381253-B2 | Solid electrolyte containing a thio-lisicon region II crystal structure | IDEMITSU KOSAN CO., LTD. (JP) | 2025-08-05 | — | — | US | disclosed |
| US-20250201909-A1 | METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE | IDEMITSU KOSAN CO.,LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| US-20250183359-A1 | CRYSTALLINE SULFIDE SOLID ELECTROLYTE AND METHOD FOR PRODUCING SAME | IDEMITSU KOSAN CO.,LTD. (JP) | 2025-06-05 | — | — | US | disclosed |
| EP-4564376-A1 | METHOD FOR PRODUCING SOLID ELECTROLYTE, AND SOLID ELECTROLYTE | Idemitsu Kosan Co.,Ltd. (JP) | 2025-06-04 | — | — | EP | disclosed |
| EP-4557317-A1 | METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE | Idemitsu Kosan Co.,Ltd. (JP) | 2025-05-21 | — | — | EP | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CYP2B6 3233/4885NPC1 4547/4885HRH3 649/4885 |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | CYP2B6 1121/4885NPC1 3728/4885HRH3 315/4885 |
| US-20260008676-A1 | METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE | CACNA1S, CACNA1A, VRK2 | CYP2B6 3587/4885NPC1 3423/4885HRH3 3808/4885 |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | CYP2B6 2113/4885NPC1 3282/4885HRH3 1935/4885 |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CYP2B6 3454/4885NPC1 4455/4885HRH3 685/4885 |
| US-12612313-B2 | Method for producing lithium halide compound | CLCN2, SLC6A12, CLIC1 | CYP2B6 3251/4885NPC1 3090/4885HRH3 2079/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | CYP2B6 2113/4885NPC1 3282/4885HRH3 1935/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | CYP2B6 53/4885NPC1 13/4885HRH3 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.